“Because That is the Right Thing to do”: A Focus Group Study of Australian Expert Perspectives on Offering Smoking Cessation Support in Lung Cancer Screening
Nicotine and Tobacco Research · 2025
DOI: 10.1093/ntr/ntae215 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nicotine and Tobacco Research, 2025. Verfasst von Nathan J Harrison und 11 weiteren Autor:innen. Beteiligte Einrichtung: Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia. Hauptthemen laut MEDLINE: Smoking Cessation, Lung Neoplasms, Early Detection of Cancer. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Health and Medical Research Council, Flinders University, Medical Research Future Fund Grant.
Abstract (Originalsprache)
Introduction
Lung cancer screening (LCS) trials, targeting people with a smoking history, have demonstrated reduced mortality. How to optimally embed evidence-based smoking cessation support in LCS, including in Australia, needs to be better understood. We sought experts’ perspectives to identify potential barriers and effective implementation strategies. Aims and Methods Perceptions of providing smoking cessation support in LCS were elicited in 24 focus groups and three individual interviews with clinicians, cancer screening program managers/policymakers, and researchers during 2021. We conducted framework analysis and mapped key topics to the updated Consolidated Framework for Implementation Research (CFIR).
Results
Experts (N = 84 participants) strongly supported capitalizing on an “opportune time” for smoking cessation and new LCS participant contact opportunities throughout the screening and assessment pathway. Many advocated for adapting existing cessation resources to the LCS setting and providing support without participant costs. Experts generally considered referral alone to established programs (eg, telephone Quitline) as insufficient, but likely helpful in follow-up, and dedicated cessation specialist roles as essential. Broader cessation messaging (via mass media/community channels) was also suggested to reinforce individualized support. Experts described inherent alignment, and an ethical responsibility, to deliver smoking cessation as a core LCS component. It was suggested that LCS-eligible participants’ varied experiences of stigma, health literacy, and motivation, be considered in cessation support. Primary care support and individualized interventions were suggested to facilitate implementation.
Conclusions
Experts considered smoking cessation support essential in LCS. The expert-identified and multi-level implementation strategies described here can directly inform smoking cessation-specific planning for Australia’s forthcoming National LCS Program.
Implications
The international literature includes few examples considering how best to provide smoking cessation support within a LCS program in advance of program commencement. Our analysis, using the updated CFIR, is one of the first to explore experts’ perspectives within this context. Experts identified multiple implementation barriers to providing smoking cessation support within and outside of an Australian LCS program, including key work infrastructure barriers, and advocated for providing tailored interventions within this program. Our foundational work in a new targeted screening program’s preimplementation phase will allow international comparisons to be made.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia.
- NHMRC Centre of Research Excellence on Achieving the Tobacco Endgame, School of Public Health, The University of Queensland, Herston, QLD, Australia.
- National Centre for Education and Training on Addiction (NCETA), Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia.
- The Daffodil Centre, a joint venture between The University of Sydney and Cancer Council NSW, Faculty of Medicine and Health, The University of Sydney, NSW, Australia.
- Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, NSW, Australia.
- Department of Thoracic Medicine, The Prince Charles Hospital, University of Queensland Thoracic Research Centre, Chermside, QLD, Australia.
ORCID-Profile: Nathan J Harrison, Henry M Marshall, Jacqueline A Bowden
Förderung
- National Health and Medical Research Council
- Flinders University
- Medical Research Future Fund Grant
- NHMRC Project Grant
- NHMRC Centre of Research Excellence on Achieving the Tobacco Endgame
- Metro North Hospital and Health Service
- NHMRC Investigator Grant
Zitieren
APA
Harrison, N. J., Dodd, R. H., Sharman, A. R., Marshall, H. M., Stone, E., Rhee, J. J., Yap, M. L., McCullough, S., Paul, C., Bowden, J. A., Bonevski, B., & Rankin, N. M. (2025). “Because That is the Right Thing to do”: A Focus Group Study of Australian Expert Perspectives on Offering Smoking Cessation Support in Lung Cancer Screening. Nicotine and Tobacco Research. https://doi.org/10.1093/ntr/ntae215
Vancouver
Harrison NJ, Dodd RH, Sharman AR, Marshall HM, Stone E, Rhee JJ, et al. “Because That is the Right Thing to do”: A Focus Group Study of Australian Expert Perspectives on Offering Smoking Cessation Support in Lung Cancer Screening. Nicotine and Tobacco Research. 2025. doi:10.1093/ntr/ntae215
BibTeX
@article{Harrison2025,
author = {Harrison, Nathan J and Dodd, Rachael H and Sharman, Ashleigh R and Marshall, Henry M and Stone, Emily and Rhee, Joel J and Yap, Mei Ling and McCullough, Sue and Paul, Christine and Bowden, Jacqueline A and Bonevski, Billie and Rankin, Nicole M},
title = {“Because That is the Right Thing to do”: A Focus Group Study of Australian Expert Perspectives on Offering Smoking Cessation Support in Lung Cancer Screening},
journal = {Nicotine and Tobacco Research},
year = {2025},
doi = {10.1093/ntr/ntae215}
}
EUVIMED